Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant appeared in South Africa for the first time. The high prevalence of its mortality in elderly patients has caused an increase in anxiety triggered by this disease in aged people. Objectives: The aim of this study is to evaluate the anxiety related-COVID-19 in the SARS-CoV-2 Omicron variant and its related factors in elderly patients who are candidates for cataract surgery. Patients and Methods: This descriptive-analytical study was conducted on 159 over 65 years old patients who are candidates for cataract surgery. Easy and accessible sampling methods were employed to select samples. Demographic characteristics sheet and the Corona Disease Anxiety Scale (CDAS) questionnaire were filled out by them. Fisher’s exact test, Mann-Whitney U and binary logistic regression tests were conducted for data analysis. Results: The results showed that out of 159 patients, 57.9% were female, with a mean age of 73.09 ± 9.64 years. The anxiety level of 70.4% of patients was mild or non-anxiety and 29.6% was moderate or severe. The correlation between anxiety related to COVID-19 with age, gender, vaccination status and history of being infected by COVID-19 was significant (P<0.05); however, the correlation with the job, place of residence and marital status were not significant (P>0.05). Conclusion: We concluded that older age, female gender, non-vaccinated and having no history of being infected by COVID-19 are the most influential factors that increase anxiety triggered by COVID-19 in elderly patients.

Introduction: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are the most recent pharmaceutical group for type 2 diabetes (T2D) treatment. Evidence indicates contradictory relationships between sodium-glucose cotransporter-2 inhibitors and bladder cancer (BC). Hence, this study aims to investigate the relationship between SGLT2 inhibitors and BC in patients with T2D. Materials and Methods: This study is a systematic review and meta-analysis based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). International databases including Cochrane, Web of Science, Scopus, PubMed, and Google Scholar were conducted for searching with keywords and without time and language limitations. The reference searching stage continued upgrading until November, 2022. Data analysis was performed with STATA 14 software. The tests with P values lower than 0.05 were considered statistically significant. Results: The four reviewed studies with a sample size comprising 497 755 individuals indicated the impact of SGLT2 inhibitors on BC of patients with T2D (OR: 0.68; 95% CI: 0.37, 1.2). The effect of dapagliflozin, canagliflozin and empagliflozin administration on the incidence of BC among the T2D patients were (OR: 0.72; 95% CI: 0.39, 1.30), (OR: 0.53; 95% CI: 0.23, 1.20), and (OR: 0.51; 95% CI: 0.20, 1.28), respectively. Conclusion: The general conclusion of this study revealed that SGLT2 inhibitors did not increase the risk of BC in T2D patients. The analysis of subgroups also indicated that the administration of dapagliflozin, canagliflozin, and empagliflozin also did not increase the risk of BC in T2D patients. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (ID=CRD42023389014).